Tesamorelin 10mg

$60.00

🔬 What Is Tesamorelin?

  • Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH).

  • It stimulates the pituitary gland to release growth hormone (GH), which in turn increases IGF-1 production.

  • Brand name: Egrifta SV.

  • It’s FDA-approved, but only for one specific medical use.

📌 Approved Use

  • Indication: Treatment of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.

  • It is not approved for general weight loss, bodybuilding, or anti-aging—though some clinics prescribe it off-label.

⚙️ Mechanism of Action

  • Mimics natural GHRH → stimulates pulsatile GH release.

  • Leads to:

    • Increased lipolysis (fat breakdown)

    • Decreased lipogenesis (fat storage)

    • Selective reduction in visceral adipose tissue (VAT) (the deep belly fat around organs, strongly linked to metabolic disease)

  • May also improve liver fat and insulin sensitivity in some patients.

📊 Clinical Effects

  • Visceral fat reduction: Average 15–20% decrease in VAT after 6 months of therapy.

  • Liver health: Studies suggest benefit in NAFLD/NASH (fatty liver disease).

  • Lean body mass: Modest increases, but not a dramatic muscle builder.

  • Metabolic impact: May improve triglycerides and cholesterol, though can raise blood sugar in some patients.

⚠️ Safety & Side Effects

Common:

  • Injection site reactions (redness, itching)

  • Joint stiffness, muscle aches

  • Peripheral edema (swelling)

  • Mild nausea

Metabolic:

  • May raise fasting blood sugar or HbA1c → caution in people with diabetes or prediabetes.

Serious:

  • Avoid in patients with active cancer (since GH/IGF-1 can promote cell growth).

  • Contraindicated in pregnancy.

✅ Key Takeaways

  • Tesamorelin = FDA-approved GHRH analog, marketed as Egrifta SV.

  • Indication: Only approved for HIV-associated lipodystrophy (visceral fat reduction).

  • Dose: 2 mg SC daily.

  • Benefits: Decreases visceral fat, modest lean mass gains, possible liver benefits.

  • Risks: Injection site irritation, joint aches, possible blood sugar elevation.

🔬 What Is Tesamorelin?

  • Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH).

  • It stimulates the pituitary gland to release growth hormone (GH), which in turn increases IGF-1 production.

  • Brand name: Egrifta SV.

  • It’s FDA-approved, but only for one specific medical use.

📌 Approved Use

  • Indication: Treatment of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.

  • It is not approved for general weight loss, bodybuilding, or anti-aging—though some clinics prescribe it off-label.

⚙️ Mechanism of Action

  • Mimics natural GHRH → stimulates pulsatile GH release.

  • Leads to:

    • Increased lipolysis (fat breakdown)

    • Decreased lipogenesis (fat storage)

    • Selective reduction in visceral adipose tissue (VAT) (the deep belly fat around organs, strongly linked to metabolic disease)

  • May also improve liver fat and insulin sensitivity in some patients.

📊 Clinical Effects

  • Visceral fat reduction: Average 15–20% decrease in VAT after 6 months of therapy.

  • Liver health: Studies suggest benefit in NAFLD/NASH (fatty liver disease).

  • Lean body mass: Modest increases, but not a dramatic muscle builder.

  • Metabolic impact: May improve triglycerides and cholesterol, though can raise blood sugar in some patients.

⚠️ Safety & Side Effects

Common:

  • Injection site reactions (redness, itching)

  • Joint stiffness, muscle aches

  • Peripheral edema (swelling)

  • Mild nausea

Metabolic:

  • May raise fasting blood sugar or HbA1c → caution in people with diabetes or prediabetes.

Serious:

  • Avoid in patients with active cancer (since GH/IGF-1 can promote cell growth).

  • Contraindicated in pregnancy.

✅ Key Takeaways

  • Tesamorelin = FDA-approved GHRH analog, marketed as Egrifta SV.

  • Indication: Only approved for HIV-associated lipodystrophy (visceral fat reduction).

  • Dose: 2 mg SC daily.

  • Benefits: Decreases visceral fat, modest lean mass gains, possible liver benefits.

  • Risks: Injection site irritation, joint aches, possible blood sugar elevation.